Skip to main
ACXP

ACXP Stock Forecast & Price Target

ACXP Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Acurx Pharmaceuticals Inc. is positioned favorably due to recent positive feedback from both the FDA and EMA regarding its antibiotic candidate, ibezapolstat (IBZ), ahead of its upcoming Phase 3 trial in adult populations. The company has demonstrated encouraging antimicrobial activity alongside a favorable safety profile for IBZ, enhancing its prospects for successful development. Additionally, the positive opinion from the Pediatric Committee of the EMA on the Pediatric Investigation Plan for IBZ’s use in children signifies strong regulatory support, further bolstering Acurx's potential for advancement in the critical antibiotic market.

Bears say

Acurx Pharmaceuticals Inc. faces significant challenges related to its clinical stage status, which introduces inherent risks associated with drug development timelines and regulatory approvals, potentially hindering revenue generation. The company's focus on a niche market of Gram-positive selective spectrum antibiotics, while addressing pressing health needs, may limit broader market appeal and competitive positioning against established antibiotic therapies. Additionally, the financial outlook is dimmed by uncertainties surrounding funding for ongoing research and development, coupled with the potential for increased operational costs in advancing its product candidates.

ACXP has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Acurx Pharmaceuticals LLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Acurx Pharmaceuticals LLC (ACXP) Forecast

Analysts have given ACXP a Strong Buy based on their latest research and market trends.

According to 1 analysts, ACXP has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Acurx Pharmaceuticals LLC (ACXP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.